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Neuropathies are severe complications of diabetes. In this issue of Neuron, Campanucci et al. report that
hyperglycemia-induced elevation of reactive oxygen species impairs synaptic transmission of sympathetic
neurons leading to diabetes-induced dysautonomias. These observations provide new insights into the
etiology of diabetic complications and suggest potential novel therapeutic approaches for neuropathies.Neuropathies are important comorbidities
of type 2 diabetes. Depending on the
affected nerves, symptoms of diabetic
neuropathy can include pain and numb-
ness in the extremities and problems
with the digestive system, urinary tract,
blood vessels, and heart. The symptoms
can be mild but may also be debilitat-
ing, even severe and sometimes fatal
(Freeman, 2005). While there is con-
sensus that diabetes-associated hyper-
glycemia leads to these various types
of neuropathies, the molecular underpin-
nings of impaired neuronal function trig-
gered by diabetes are ill-defined.
In this issue of Neuron, Campanucci
et al. (2010) provide evidence that an
elevation of cellular reactive oxygen spe-
cies (ROS) during hyperglycemia plays
an important role in the depression of
synaptic transmission in sympathetic
neurons, which may be responsible for
the development of neuropathies. Syn-
aptic transmission in sympathetic effer-
ents occurs via activation of nicotinic
acetylcholine receptors (nAchR) in sym-
pathetic ganglions, such as the superior
cervical ganglion (SCG). These ionotropic
receptors are heteromultimers consisting
of different components, including a, b,
g, and d subunits. Upon acetylcholine
(Ach) binding, nAChR activation enables
cation (primarily sodium) entry to the
cytosol, leading to membrane depolariza-
tion, which increases excitatory postsyn-
aptic potentials (EPSP) and elevates
excitatory neurotransmission (Figure 1).
In this study, Campanucci et al. first
showed that in the streptozotocin-
induced diabetes model, in whichinsulin-producing pancreatic beta cells
are eliminated, Ach-evoked EPSPs were
significantly depressed in sympathetic
neurons of the superior cervical ganglia
(SCG) compared to nondiabetic control
mice. This decreased excitatory neuro-
transmission in diabetic mice was associ-
ated with a reduction in sympathetic
nerve activity leading to decrease in heart
rate and loss of thermoregulation. To test
whether the overall outcome of the inter-
vention is due to diminished insulin levels
(loss of pancreatic beta cells) or elevated
circulating glucose levels (the conse-
quence of insulin depletion), they tested
sympathetic activity in animals with natu-
rally occurring diabetes, mice that have
no circulating adipose-derived leptin
(ob/ob mice) or long form of leptin recep-
tors (db/dbmice). In these animals, hyper-
glycemia is associated with high levels
of insulin. In both ob/ob and db/db
mice, depressed synaptic transmission
in the sympathetic nervous system was
observed. Since alterations in synaptic
transmission were observed both in type
I (lack of insulin) and type II (elevated
insulin) diabetic models, their findings
argue for the role of hyperglycemia rather
than insulin in this pathophysiological
process.
To understand the mechanism by
which hyperglycemia could induce a
depression in synaptic transmission, the
authors used an in vitro approach. First,
they showed that exposure of cultured
neonatal SCG neurons to high glucose
levels induced an increased staining of
4-hydroxy-2-nonenal (HNE), a major pro-
duct of endogenous lipid peroxidation.NeuronThen, to test whether this hypergly-
cemia-induced ROS elevation causes
a use-dependent inactivation of nAChRs,
they recorded from SCG neurons with
whole-cell voltage clamp using a high
(25mM) and a lower (5 mM) concentration
of glucose in the media. When neurons
where exposed to high glucose levels,
repeated application of Ach caused a
use-dependent rundown of the Ach-
evoked current compared to control neu-
rons maintained at lower glucose levels.
To test whether ROS are responsible for
this effect, neurons were then treated
with antioxidants such as a-lipoic acid
and catalase and Ach-evoked currents
were recorded. Pretreatment of neurons
with antioxidants prevented the rundown
of the Ach-evoked currents in neurons
exposed to high glucose levels, thus sug-
gesting that hyperglycemia-induced ROS
were responsible for the detrimental
effect on nAChRs function.
To understand the putative molecular
mechanism of the inactivation of nAChRs
by ROS, Campanucci et al. studied the
known effect of ROS on the oxidation of
cysteine (Cys) residues on the a subunit
of nAChRs. They transfected sympathetic
neurons of a3 KO mice (nonfunctional
nAChRs) with either a vector expressing
the a3 wild-type receptor (a3 WT) or with
a mutated receptor in which the Cys at
position 239 in the a3 subunit was
replaced by an alanine residue (a3 C239A).
When a3WT neurons were exposed to
highglucose levels, repeatedAchapplica-
tion caused the rundown of the
ACh-evoked currents. However, when
the a3C239A-transfected neurons were66, June 24, 2010 ª2010 Elsevier Inc. 809
Figure 1. ROS Action on Sympathetic Neurons
(A) Preganglionic efferents of the sympathetic nervous system
activate sympathetic neurons of the superior cervical ganglia
(SCG) via activation of nictotinic acethylcoline receptors
(nAchR). These postsynaptic receptors have various subunits:
a, b, d, g. SCG efferents affect various peripheral tissue func-
tions, including increasing heart rate, thermogenesis, and liver
gluconeogenesis.
(B) During sustained hyperglycemia, glucose-generated free
radicals (O2
o–) oxidize cysteine residues in the a subunit (red)
of the nAchR through which they diminish sympathetic
synaptic transmission and trigger consequent alterations in
peripheral tissue function. Glucose-generated ROS may arise
fromwithin SCG neurons via substrate oxidation or from extra-
cellular sources.
(C) Mutating the a subunit of the nAchR (yellow) by eliminating
cysteine residues prevents free-radical-induced impairment of
nAchR signaling allowing continued synaptic transmission
despite hyperglycemia-induced free-radical generation.
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Previewsexposed to high glucose levels, the
Ach-evoked currents were stable,
indicating that the inactivation of the
nAchR by hyperglycemia-induced
ROS production involves the Cys at
position 239 of the a3 subunit.
Finally, to test whether the Cys
residue was responsible for the
depression of synaptic transmission
in vivo, they infected a3 KO mice
with adenoviral vectors expressing
either the a3WT or the a3C239A,
induced diabetes by STZ injection,
and compared the nerve-evoked
EPSPs in SCG neurons. In diabetic
a3 KO mice infected with a3WT, the
nerve-evoked EPSPs were signifi-
cantly reduced 2 weeks after the
onset of diabetes. However, in dia-
betic a3 KO mice infected with
a3C239A, the nerve-evoked EPSPs
were not different than those of
nondiabetic WT mice. In addition,
while the diabetic a3 KO mice in-
fected with a3WT showed a reduced
sympathetic drive of the heart
and had impaired thermoregulation
in cold, the diabetic a3 KO mice
infected with a3C239A showed no
differences in these sympathetic
adaptations.
The adaptive process of sympa-
thetic activation enables an organ-
ism to utilize its internal energy sour-
ces to launch a response in self
defense to support survival. Beyond
the aforementioned effects on heart
rate and thermoregulation, both of
which enable efficient and rapid
transport of nutrients to the muscles
and brain, increased sympathetic
tone promotes acute gluconeogen-
esis and glucose release from
the liver to provide an internal
source of fuel. While these adaptive
responses are very reasonable at
the time of predatory threat or fast-
ing, when reliance on internal energy
sources for survival is critical, to
maintain such a sympathetic tone
during diabetes would contribute
to elevated circulating glucose
levels. In most cases of type 2 dia-
betes, hyperglycemia is the conse-
quence of both overnutrition andincreased hepatic glucose production
and release. Thus, from this perspec-
tive, a sustained hyperglycemia-induced810 Neuron 66, June 24, 2010 ª2010 Elseviedecrease in the sympathetic outflow, the
focus of the paper, may actually be seen
as a positive adaptation whereby it is anr Inc.attempt to decrease liver production
and release of glucose to diminish
hyperglycemia. It remains to be
seen whether restoration of the
sympathetic outflow in diabetes, as
being proposed by Campanucci
et al. (2010), would actually be bene-
ficial or detrimental for glycemic
control in diabetes.
The paper by Campanucci et al.
assigns a critical role for ROS in
impairing sympathetic synaptic
transmission. They found that treat-
ment of neurons with antioxidants,
a-lipoic acid and catalase, during
hyperglycemia, prevented synaptic
depression, thus indicating that
ROS formation in hyperglycemic
conditions is an important regulator
of neuronal function. Whether the
ROS affecting nAchRs are arising
from within SCG neurons or extra-
cellularly (Figure 1) is a critical ques-
tion that needs to be resolved
to better understand therapeutic
potentials of the findings.
In recent years, it has become
more evident that ROS are not
merely harmful by-products of
substrate oxidation, but also play
vital roles in regulating neuronal
responses and related behaviors
as well as controlling peripheral
tissue function (Andrews et al.,
2008; Benani et al., 2007; Jaillard
et al., 2009). It is tempting to draw
some comparison between the
effects of ROS on the final output
component of the sympathetic ner-
vous system (Campanucci et al.,
2010) to ROS-regulated neurons in
central regions of the brain presyn-
aptic to the sympathetic nervous
system (Elias et al., 1998). Themedi-
obasal hypothalamus provides an
important input for the autonomic
nervous system (Elmquist et al.,
1999). A subpopulation of neurons
in the arcuate nucleus that produce
pro-opiomelanocortin (POMC) are
critical mediator’s of leptin’s effect
on feeding behavior, energy expen-
diture, and the sympathetic nervous
system (Gao and Horvath, 2007).
These cells are connected withthoracic, preganglionic sympathetic neu-
rons (Elias et al., 1998; Elmquist et al.,
1999), and their activity is supported by
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Previewshigh ROS levels (Benani et al., 2007; An-
drews et al., 2008; Horvath et al., 2009;
Jaillard et al., 2009). Repeated activation
of POMC neurons and related behaviors
and autonomic adaptations occur daily.
Short-term ROS peaks appear to be
fundamental for evoking a proper behav-
ioral, endocrine, and autonomic response
to nutrient intake and are likely to be asso-
ciated with short-term peaks of ROS
generation in sympathetic neurons as
well. On the other hand, prolonged expo-
sure to hyperglycemia-triggered ROS
clearly impairs sympathetic neuronal
functions and outflow due to oxidation of
the Cys residue of cholinergic receptors
(Campanucci et al., 2010). Whether sim-
ilar impairments of receptor activation
(not necessarily cholinergic receptors)
occur in POMC neurons in response to
sustained ROS generation, when an ani-
mal is on high fat diet for example, is a
highly relevant question to pursue.In summary, the observations of Cam-
panucci et al. (2010) shed new light on
the etiology and offer potential new thera-
peutic approaches for diabetic neuropa-
thies. Questions remain, however, regard-
ing the source of ROS that impair nAchRs
function: whether ROS are from intracel-
lular or extracellular origin and whether
ROS are the product of glucose oxidation
or emerge from other metabolic pro-
cesses. Further work is also needed to
clarify whether effects of neuropathies
promoted by diabetes influence hepatic
glucose production and output and how
restoration of sympathetic outflow would
impact these critical processes.REFERENCES
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Disabled-1 is a key signalingmolecule in the Reelin pathway that plays a critical role in neuronalmigration and
positioning during brain development. In this issue of Neuron, Yano et al. demonstrate that the neuron-
specific RNA binding protein Nova2 contributes to neuronal migration by regulating alternative splicing of
disabled-1.Neuronal migration and positioning in the
developing brain is a complicated pro-
cess that requires well-orchestrated inter-
actions among migrating neurons, radial
glial cells, and postmigration neurons.
The Reelin pathway controls neuronal
migration in the developing cortex, cere-
bellum, and hippocampus, and it has
been implicated in human brain disorders
such as lissencephaly, schizophrenia,
bipolar disorder, autism, and temporal
lobe epilepsy. Genetic and biochemical
studies have helped elucidate the bio-
chemical mechanisms responsible for
Reelin signaling (for review, see Rice andCurran 2001; Ayala et al., 2007). Reelin is
a protein ligand that binds two receptors:
apoER2 and VLDLR. Binding of Reelin to
these receptors triggers tyrosine phos-
phorylation of disabled-1 (Dab1) by Fyn
and Src. Tyrosine phosphorylated Dab1
recruits downstream signaling molecules
including the SH2/SH3 domain-contain-
ing adaptor proteins, Crk and CrkL, as
well as other signaling components,
before it is degraded by the ubiquitin-pro-
teasome pathway. These adaptor
proteins induce cytoskeletal changes
and other cellular responses necessary
for appropriate migration and positioningof neurons. Therefore, Dab1 plays
a central role in Reelin signaling, and
failure of either expression or phosphory-
lation of Dab1 leads to severe defects in
neuronal migration, similar to those
observed in the absence of Reelin or
Reelin receptors. In this issue of Neuron,
Yano et al. present a novel mechanism
of Dab1 regulation involving alternative
splicing by Nova2.
Nova2 is an RNA-binding protein
specifically expressed in neurons. It was
identified as an autoantigen in paraneo-
plastic opsoclonus myoclonus ataxia
(POMA) (Yang et al., 1998), a neurologic66, June 24, 2010 ª2010 Elsevier Inc. 811
